Navigation Links
Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
Date:11/19/2008

KVISTGARD, Denmark, November 19 /PRNewswire-FirstCall/ -- Bavarian Nordic has invoiced the U.S. authorities for another milestone payment of USD 25 million as allowed under the RFP-3 contract to manufacture and deliver 20 million doses of the company's IMVAMUNE(R) smallpox vaccine. This milestone payment was triggered by the recent submission of a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects, which is part of the regulatory package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency. With this, Bavarian Nordic is an important step closer to fulfilling the conditions for initiating delivery of IMVAMUNE(R) in 2009.

The income will be recognised as revenue in the financial statements for 2008.

With this payment, Bavarian Nordic has so far invoiced a total of USD 125 million in advance- and milestone payments under the RFP-3 contract, of which USD 50 million has not yet been recognised in the income statement.

This announcement does not change Bavarian Nordic's previously announced financial guidance for 2008.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "Since the award of the RFP-3 we have successfully met all agreed objectives in the contract with the U.S. Department of Health and Human Services and we find this very satisfactory. The submission of these clinical data concludes the data package that may support the use of IMVAMUNE(R) in a declared emergency and marks an important event for the company this year. This submission is part of the company's plan to support the delivery of IMVAMUNE(R) which is planned to start during 2009".

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The c
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
4. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
5. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
6. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
7. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
8. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
9. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
10. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
11. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Researchers in California today (Oct. 17) report development of ... waves wirelessly and converts them to sound signals through ... nanotube radio device is thousands of times smaller than ... an important step in the evolution of nano-electronics and ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today reported ... Total revenues in the third quarter of 2007 ... quarter of 2006. Total revenues in the first,nine months ... in the,first nine months of 2006. Revenues in the ...
... Oct. 17 Navitas Cancer Rehabilitation Centers,of America, ... and,comprehensive cancer rehabilitation services, is pleased to announce ... Corporate Medical Director. In addition to currently ... Paul area, Dr. Gesme has served as the ...
Cached Biology Technology:Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Navitas Names Dr. Dean Gesme as Medical Director 2
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... LAFAYETTE, Ind. - Sanitizing the outside of produce may not ... Purdue University study that demonstrated that Salmonella and E. ... E. coli 0157:H7 was present in tissues of mung ... seeds were contaminated with the pathogens prior to planting. Amanda ...
... an international team including professor John Graves of the Virginia ... tunas and billfishes are threatened and in need of further ... Science magazine,s Policy Forumis the first study of ... International Union for Conservation of Nature (IUCN). ,The IUCN Red ...
... time when instead of just drinking that morning cup of ... of preventing harmful sun damage or skin cancer., A new ... skin cancers at the molecular level by inhibiting a protein ... based on what they have learned studying mice, caffeine applied ...
Cached Biology News:E. coli, salmonella may lurk in unwashable places in produce 2Study helps assess global status of tuna and billfish stocks 2Study helps assess global status of tuna and billfish stocks 3More evidence that caffeine lowers risk of skin cancer 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: